Quantitative Proteomics Identifies TCF1 as a Negative Regulator of Foxp3 Expression in Conventional T Cells.

Immunology Molecular Biology Molecular Mechanism of Gene Regulation Proteomics

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
22 May 2020
Historique:
received: 03 03 2020
revised: 02 04 2020
accepted: 29 04 2020
pubmed: 19 5 2020
medline: 19 5 2020
entrez: 19 5 2020
Statut: ppublish

Résumé

Regulatory T cells are important regulators of the immune system and have versatile functions for the homeostasis and repair of tissues. They express the forkhead box transcription factor Foxp3 as a lineage-defining protein. Negative regulators of Foxp3 expression are not well understood. Here, we generated double-stranded DNA probes complementary to the Foxp3 promoter sequence and performed a pull-down with nuclear protein in vitro, followed by elution of bound proteins and quantitative mass spectrometry. Of the Foxp3-promoter-binding transcription factors identified with this approach, one was T cell factor 1 (TCF1). Using viral over-expression, we identified TCF1 as a repressor of Foxp3 expression. In TCF1-deficient animals, increased levels of Foxp3

Identifiants

pubmed: 32422593
pii: S2589-0042(20)30312-6
doi: 10.1016/j.isci.2020.101127
pmc: PMC7229326
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101127

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing financial interests.

Références

Nat Commun. 2011;2:269
pubmed: 21468021
J Exp Med. 2017 Jan;214(1):39-47
pubmed: 27923906
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3472-E3480
pubmed: 28396406
Nat Genet. 2001 Jan;27(1):18-20
pubmed: 11137992
J Allergy Clin Immunol. 2018 Sep;142(3):728-743
pubmed: 30195378
J Exp Med. 2019 Apr 1;216(4):847-866
pubmed: 30837262
Sci Immunol. 2019 Oct 25;4(40):
pubmed: 31653719
Nat Commun. 2016 Feb 19;7:10789
pubmed: 26892542
Front Immunol. 2012 May 10;3:113
pubmed: 22590469
Immunity. 2018 May 15;48(5):1046-1059.e6
pubmed: 29752063
Nat Immunol. 2013 Mar;14(3):230-7
pubmed: 23334790
J Exp Med. 2007 Jul 9;204(7):1543-51
pubmed: 17591856
Nat Genet. 2001 Jan;27(1):20-1
pubmed: 11137993
Nature. 2012 Feb 08;482(7385):395-9
pubmed: 22318520
Immunity. 2020 Feb 18;52(2):295-312.e11
pubmed: 31924477
Nat Immunol. 2012 Oct;13(10):1010-9
pubmed: 22922362
Immunity. 2010 Aug 27;33(2):229-40
pubmed: 20727791
Bioinformatics. 2000 Nov;16(11):1046-7
pubmed: 11159318
Immunity. 2012 Dec 14;37(6):998-1008
pubmed: 23200824
J Immunol. 2010 Jul 15;185(2):1071-81
pubmed: 20554955
J Clin Invest. 2011 Nov;121(11):4503-15
pubmed: 21965331
J Exp Med. 2009 Nov 23;206(12):2701-15
pubmed: 19917773
J Exp Med. 2009 Oct 26;206(11):2329-37
pubmed: 19841090
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6659-64
pubmed: 16617117
Immunity. 2013 Aug 22;39(2):298-310
pubmed: 23954131
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
J Immunol. 2015 Oct 1;195(7):3058-70
pubmed: 26324778
Nature. 2010 Feb 11;463(7282):808-12
pubmed: 20072126
Eur J Immunol. 2007 Jan;37(1):129-38
pubmed: 17154262
Immunity. 2012 Nov 16;37(5):785-99
pubmed: 23123060
PLoS One. 2008 Feb 20;3(2):e1612
pubmed: 18286169
J Immunol. 2007 Jan 1;178(1):280-90
pubmed: 17182565
J Clin Invest. 2003 Nov;112(9):1437-43
pubmed: 14597769
PLoS Biol. 2007 Feb;5(2):e38
pubmed: 17298177
Nat Immunol. 2008 Feb;9(2):194-202
pubmed: 18157133
Nat Genet. 2001 Jan;27(1):68-73
pubmed: 11138001
Nat Immunol. 2016 Jun;17(6):695-703
pubmed: 27111144
Nat Immunol. 2017 Oct;18(10):1160-1172
pubmed: 28783152
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Nat Immunol. 2017 Feb;18(2):173-183
pubmed: 27992401
Genome Res. 2009 Feb;19(2):284-93
pubmed: 19015324
Nature. 1995 Mar 2;374(6517):70-4
pubmed: 7870176
Immunity. 2011 Sep 23;35(3):337-48
pubmed: 21924928
J Exp Med. 2010 Sep 27;207(10):2113-25
pubmed: 20855499
Immunol Rev. 2011 May;241(1):260-8
pubmed: 21488902
Cell Rep. 2019 Jun 18;27(12):3629-3645.e6
pubmed: 31216480
Nat Immunol. 2010 Jul;11(7):618-27
pubmed: 20467422
PLoS One. 2015 May 15;10(5):e0127038
pubmed: 25978037
Nature. 2011 Aug 03;476(7358):63-8
pubmed: 21814277
Nat Commun. 2019 Apr 8;10(1):1621
pubmed: 30962454
J Exp Med. 2010 Jul 5;207(7):1381-91
pubmed: 20439537
Immunity. 2009 Dec 18;31(6):932-40
pubmed: 20064450
Blood. 2007 May 15;109(10):4368-75
pubmed: 17227828
PLoS Genet. 2015 Jun 24;11(6):e1005251
pubmed: 26107960
J Immunol. 2006 Mar 15;176(6):3593-602
pubmed: 16517728
J Exp Med. 2012 Aug 27;209(9):1529-35
pubmed: 22908322
Immunity. 2013 May 23;38(5):881-95
pubmed: 23499491
Curr Top Microbiol Immunol. 2014;381:83-124
pubmed: 24831347

Auteurs

Michael Delacher (M)

Chair for Immunology, Regensburg University, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Regensburg Center for Interventional Immunology (RCI), Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Melanie M Barra (MM)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Yonatan Herzig (Y)

Department of Immunology, Weizmann Institute of Science, 234 Herzl Street, 76100 Rehovot, Israel.

Katrin Eichelbaum (K)

European Molecular Biology Laboratory, Meyerhofstraße 1, 69117 Heidelberg, Germany.

Mahmoud-Reza Rafiee (MR)

European Molecular Biology Laboratory, Meyerhofstraße 1, 69117 Heidelberg, Germany.

David M Richards (DM)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Ulrike Träger (U)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Ann-Cathrin Hofer (AC)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Alexander Kazakov (A)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Kathrin L Braband (KL)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Marina Gonzalez (M)

Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

Lukas Wöhrl (L)

Regensburg Center for Interventional Immunology (RCI), Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.

Kathrin Schambeck (K)

Regensburg Center for Interventional Immunology (RCI), Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany.

Charles D Imbusch (CD)

Faculty of Biosciences, Heidelberg University, Im Neuenheimer Feld 234, 69120 Heidelberg, Germany; Division of Applied Bioinformatics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany.

Jakub Abramson (J)

Department of Immunology, Weizmann Institute of Science, 234 Herzl Street, 76100 Rehovot, Israel.

Jeroen Krijgsveld (J)

European Molecular Biology Laboratory, Meyerhofstraße 1, 69117 Heidelberg, Germany; Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; Medical Faculty, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany.

Markus Feuerer (M)

Chair for Immunology, Regensburg University, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Regensburg Center for Interventional Immunology (RCI), Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany; Immune Tolerance Group, Tumor Immunology Program, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Electronic address: markus.feuerer@ukr.de.

Classifications MeSH